Welcome to our dedicated page for MetaVia news (Ticker: MTVA), a resource for investors and traders seeking the latest updates and insights on MetaVia stock.
MetaVia Inc (MTVA) is a clinical-stage biotechnology leader developing innovative treatments for cardiometabolic diseases, including metabolic dysfunction-associated steatohepatitis (MASH) and obesity. This page provides investors and industry professionals with timely updates on the company’s clinical trials, strategic partnerships, and regulatory milestones.
As a centralized resource for MTVA news, we prioritize transparency in reporting developments related to key programs like DA-1241 (GPR119 agonist) and DA-1726 (oxyntomodulin analog). Users will find verified updates on trial phases, licensing agreements, and peer-reviewed research outcomes essential for informed decision-making.
Content categories include clinical progress reports, financial disclosures, executive commentary, and scientific publications. All materials are curated to meet the needs of stakeholders requiring accurate, up-to-date information on this innovative biotech’s pipeline.
Bookmark this page to stay informed about MetaVia’s advancements in addressing complex metabolic disorders through groundbreaking pharmaceutical research. Regularly updated to reflect the latest verified developments.
MetaVia (Nasdaq: MTVA) announced that data from its Phase 2a clinical trial of DA-1241, a novel GPR119 agonist, will be presented as a late-breaking poster at the EASL Congress 2025 in Amsterdam (May 7-10, 2025). The presentation will focus on the drug's hepatoprotective and glucose-regulating effects in patients with presumed metabolic dysfunction-associated steatohepatitis (MASH) from a 16-week randomized placebo-controlled trial.
The presentation titled 'DA-1241, a GPR119 Agonist, Demonstrates Hepatoprotective and Glucose-Regulating Effects in a 16-week Randomized Placebo-Controlled Trial in Presumed MASH Patients' will be delivered by Dr. Rohit Loomba from the University of California, San Diego. The poster will be available on MetaVia's website following the presentation.
MetaVia (Nasdaq: MTVA) reported additional positive top-line results from Phase 1 Multiple Ascending Dose (MAD) study of DA-1726, its novel 3:1 ratio GLP-1 and glucagon dual receptor agonist for obesity treatment. The 28-day, 36-subject trial demonstrated:
- Dose-dependent body weight reduction across 8-32mg range, with maximum -6.3% and mean -4.3% weight loss at 32mg dose by Day 26
- No significant cardiovascular effects observed, with most treatment groups showing slight decrease in heart rate
- Strong safety profile with only mild gastrointestinal adverse events in 4/6 subjects at 32mg dose, resolving within 24 hours
The drug showed promising results compared to current GLP-1 agonists, with early satiety observed in 83% of subjects at 32mg dose. Additional cohorts are being added to determine maximum tolerated dose, and a Phase 1 Part 3 study is planned to evaluate DA-1726 in patients who discontinued Wegovy®.
MetaVia (NASDAQ: MTVA) announced positive results from its 4-week Phase 1 multiple ascending dose (MAD) trial of DA-1726, a novel dual receptor agonist for obesity treatment. The 32mg dose cohort demonstrated a maximum weight loss of 6.3% and mean weight loss of 4.3% at Day 26 (p=0.0005), with no titration required.
Key findings include:
- Maximum waist circumference reduction of 3.9 inches and mean reduction of 1.6 inches at Day 33
- Maximum lowering of fasted glucose of -18 mg/dL and mean lowering of -5.3 mg/dL
- 25% of subjects experienced mostly mild gastrointestinal adverse events
- No treatment-related discontinuations or serious adverse events
The company plans to conduct Phase 1 Part 3 study investigating DA-1726 on Wegovy early drop-out patients, aiming to demonstrate superior tolerability and safety. Additional cohorts will be added to determine maximum tolerated dose.
MetaVia (NASDAQ: MTVA) announced its 2024 financial results and corporate updates. The company reported significant progress in its cardiometabolic drug development programs:
Key highlights include positive Phase 2a trial results for DA-1241 in MASH treatment, showing ALT level reduction and improved HbA1C levels. The company expects top-line data from Phase 1 MAD Part 2 trial of DA-1726 for obesity treatment in April 2025.
Financial results show:
- R&D expenses increased to $21.6M from $9.2M in 2023
- Net loss of $27.6M ($3.56 per share) compared to $12.5M in 2023
- Cash position of $16.0M, expected to fund operations into Q3 2025
MetaVia (NASDAQ: MTVA) announced it will hold an Advisory Committee meeting at the 9th Annual MASH-TAG 2025 Conference to discuss previously announced positive top-line 16-week results from their Phase 2a clinical trial. The trial evaluated DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist, in patients with presumed metabolic dysfunction-associated steatohepatitis (MASH).
The conference is being held from January 9-11 at the Chateaux Deer Valley in Park City, Utah. MetaVia's management and clinical team will be available in the Exhibit Hall to discuss the trial results, and the presentation will be accessible on the company's website.
MetaVia (Nasdaq: MTVA) announced its participation as a Sponsor and Exhibitor at the 9th Annual MASH-TAG 2025 Conference, scheduled for January 9-11 at the Chateaux Deer Valley in Park City, Utah. This announcement follows the company's recent disclosure of positive top-line 16-week results from their Phase 2a clinical trial of DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist, in patients with presumed metabolic dysfunction-associated steatohepatitis (MASH). The company's management and clinical team will be present at the conference's Exhibit Hall to discuss the trial results.
MetaVia (NASDAQ: MTVA) announced positive top-line results from its Phase 2a clinical trial of DA-1241 in patients with presumed metabolic dysfunction-associated steatohepatitis (MASH). The trial demonstrated that DA-1241 (100mg) achieved statistically significant reduction in ALT levels at weeks 4 and 8, with near-significant reduction at week 16.
Key findings include statistically significant improvements in CAP Score and HbA1c levels at Week 16. The drug showed strong safety profile with mostly mild adverse events and no drug-related serious adverse events. The study involved 109 randomized patients across two parts: testing DA-1241 alone and in combination with sitagliptin.
MetaVia (Nasdaq: MTVA), a clinical-stage biotechnology company specializing in cardiometabolic diseases, has announced its participation in the upcoming Emerging Growth Conference. The company's President and CEO Hyung Heon Kim, along with CFO Marshall H. Woodworth, will deliver a company update on December 4, 2024, at 4:10 pm ET.
The presentation will include a Q&A session, with attendees able to submit questions either in advance via email or during the event. Interested parties can register online to attend the virtual conference, with additional opportunities available for private management meetings.
